8-K filing — Spero Therapeutics, Inc. (SPRO)
Filed: 2026-08-28 AccNo: 0001193125-26-374788 Size: 148 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Spero Therapeutics shares are trading lower. The company announced an exclusive license agreement with Innovent Biologics for SP001, a third‑gen Fc‑silent anti‑CD40L antibody.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading